Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
W Timothy GarveyAndreas L BirkenfeldDror DickerGeltrude MingroneSue D PedersenAltynai SatylganovaDorthe SkovgaardDanny SugimotoCamilla JensenOfri MosenzonPublished in: Diabetes care (2020)
In individuals with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg as an adjunct to IBT was superior to placebo regarding weight loss and improved glycemic control despite lower doses of basal insulin and without increases in hypoglycemic events.